14 August 2018

LSIPR 50 2018: Roy Waldron

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Novo’s semaglutide protection weakens after European ruling

13 October 2026 Generic challengers have scored a win against the Danish company after an appeals board revoked a key patent covering the cardiovascular use of semaglutide. The decision strips away another layer of protection as generic manufacturers hunt down the semaglutide franchise.

MedTech

Boston Scientific expands dispute with J&J unit over cardiac-access technology

12 October 2026 The two major medical device makers are clashing over Atraverse’s Hotwire system, with Boston Scientific claiming the product infringes its patented radiofrequency transseptal-access technology, used in heart surgery.

Careers

Brazilian firm appoints patent strategist to lead department

12 October 2026 Ouro Preto Paranhos has brought in a licensed pharmacist with more than 26 years of intellectual property experience to lead the patent practice at the Rio de Janeiro firm.

More features

MSD’s Keytruda hit by eight-country ban across Europe

Non-profit sues Cambrex over anticancer drug manufacturing trade secrets

Inside the deal boom: LSIPR’s five-part M&A series—all in one place

Amgen hit with lawsuit over its proposed Opdivo biosimilar

Beyond the primary patent: How pharma can build competitive barriers

Built to be bought? What makes companies acquisition-ready

UK firm hires head of IP with commercial and technical nous

Tempus AI bid to derail DNA patent case hits snag

LSIPR 50 2018: Roy Waldron

More on this story

Editor's picks

Editor's picks

More features